StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The company has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- Trading Halts Explained
- MarketBeat Week in Review – 8/5 – 8/9
- What is a Special Dividend?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Investing in Commodities: What Are They? How to Invest in Them
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.